Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity.
Carla M M Prado, Vickie E Baracos, Linda J McCargar...
https://pubmed.ncbi.nlm.nih.gov/17545532/Actively Recruiting
Led by Institut du Cancer de Montpellier - Val d'Aurelle · Updated on 2025-02-13
150
Participants Needed
1
Research Sites
156 weeks
Total Duration
Researchers are developing a prospective clinico-biological database focused on cachexia and undernutrition in patients with colon cancer. Cachexia is a serious syndrome marked by rapid, involuntary weight loss affecting fat and muscle tissues, which can contribute to treatment failure and increased mortality. This study aims to improve understanding of cachexia to enhance patient care and survival by integrating nutritional approaches and clinical nutrition advancements. Participants will have blood samples collected at the start of the study and every six months during treatment, alongside standardized clinical data entered into a database. This collection supports future research projects aimed at tailoring management strategies for patients with colon cancer-related cachexia. The study involves patients treated at a regional cancer institute and monitors biological and clinical risk factors over six years. During the study, participants will undergo regular clinical assessments and blood sample collections to track nutritional and metabolic changes. Researchers will measure the number of clinical and biological risk factors for colorectal cancer until the studys completion. This ongoing monitoring will help identify factors influencing treatment response and toxicity. Participation continues for up to six years, allowing long-term data collection and follow-up.
CONDITIONS
A Clinico-biological Database in Cachexia in Patients With Colon Cancer
J
Jean-Pierre Bleuse, MD
A
Aurore Moussion
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Institut du Cancer de Montpellier - Val d'Aurelle
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 6 years
Participants provide blood samples at inclusion and during treatment every 6 months, while clinical data is also collected into a database.
Blood samples collected every 6 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Carla M M Prado, Vickie E Baracos, Linda J McCargar...
https://pubmed.ncbi.nlm.nih.gov/17545532/S Antoun, V E Baracos, L Birdsell...
https://pubmed.ncbi.nlm.nih.gov/20089558/C Chambrier, F Sztark, Société Francophone de nutrition clinique et métabolisme (SFNEP)...
https://pubmed.ncbi.nlm.nih.gov/23107793/Vickie E Baracos, Tony Reiman, Marina Mourtzakis...
https://pubmed.ncbi.nlm.nih.gov/20164322/Alisdair J MacDonald, Carolyn A Greig, Vickie Baracos
https://pubmed.ncbi.nlm.nih.gov/21986910/Carla M Prado, Michael B Sawyer, Sunita Ghosh...
https://pubmed.ncbi.nlm.nih.gov/23966429/Lisa Martin, Laura Birdsell, Neil Macdonald...
https://pubmed.ncbi.nlm.nih.gov/23530101/Institut du Cancer de Montpellier - Val d'Aurelle
Lead Sponsor